Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon
and other cancer in patients with Lynch syndrome. Each of the three injections in Tri-Ad5
vaccine contain a different substance that is in precancer and cancer cells. Injecting these
substances may cause the immune system to develop a defense against cancer that recognizes
and destroys any precancer and cancer cells that produce these proteins in the future. N-803
may increase immune responses to other vaccines. Giving Tri-Ad5 in combination with immune
enhancing N-803 may lower the change of developing colon and other cancer in patients with
Lynch syndrome.